Article
Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.
International journal of cancer - 15 Dec 2022
Watanabe Jun, Maeda Hiromichi, Nagasaka Takeshi, Yokota Mitsuru, Hirata Keiji, Akazawa Naoya, Kagawa Yoshinori, Yamada Takeshi, Shiozawa Manabu, Ando Takayuki, Kato Takeshi, Mishima Hideyuki, Sakamoto Junichi, Oba Koji, Nagata Naoki
Abstract excerpt
This multicenter single-arm, phase II study evaluated the efficacy and safety of uninterrupted panitumumab usage combined with cytotoxic doublets for unresectable/metastatic colorectal cancer (mCRC). Additionally, clinical value of the RAS/BRAF mutation status in circulating cell-free DNA (ccfDNA) was evaluated; this evaluation was measured independently of the protocol treatment. Eligible patients with RAS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.